First Brands Group debt targeted by Apollo Global Management - report
Vyome Holdings, Inc. (NASDAQ:HIND), currently valued at $13.09 million, announced the completion of its previously disclosed merger with Vyome Therapeutics, Inc. The transaction was finalized before the open of trading on August 15, following an agreement signed on July 8, 2024. The stock has shown resilience this year with a 6.61% year-to-date return. As a result of the merger, Vyome Therapeutics became a wholly owned subsidiary of Vyome Holdings, and the company changed its name from ReShape Lifesciences Inc. to Vyome Holdings, Inc. The stock currently trades at $14, near its 52-week high of $14.89. InvestingPro subscribers can access detailed merger analysis and comprehensive financial metrics to evaluate the combined entity’s potential.
On Tuesday, the company filed a Form 8-K with the Securities and Exchange Commission to provide additional information related to the merger. The filing includes Vyome Therapeutics’ financial statements for the quarter ended June 30, 2025, a management discussion and analysis of financial condition and results of operations for the same period, and unaudited pro forma condensed combined financial statements reflecting the effects of the merger. These documents are incorporated by reference into Vyome Holdings’ shelf registration statement on Form S-3, filed on May 9, 2025.
Vyome Holdings’ common stock continues to trade on the Nasdaq Capital Market under the symbol HIND. The information in this article is based on a press release statement contained in the company’s SEC filing.
In other recent news, Vyome Holdings, Inc. announced a significant expansion of its at-the-market public offering, increasing the potential sale of its shares to $12 million from the previous limit of approximately $3.4 million. This development comes as part of an amended Equity Distribution Agreement with Maxim Group LLC. Additionally, Vyome Holdings has appointed Kreit & Chiu CPA LLP as its new independent registered public accounting firm, replacing Haskell & White LLP, with no reported disagreements on financial practices. The company is also reviewing strategic alternatives for its majority-owned subsidiary, Livechain Inc., as it explores different options following its Nasdaq listing. Vyome Holdings recently completed a merger with ReShape Lifesciences, leading to a new listing on Nasdaq under the ticker "HIND" and a 1-for-4 reverse stock split of ReShape’s common stock. In conjunction with this, Vyome will replace ReShape’s leadership team with a new Board of Directors, including several MIT alumni. Furthermore, Vyome has entered into a memorandum of understanding with Embryyo Technologies to explore opportunities in the AI-enabled medical device market. These developments reflect Vyome’s ongoing strategic initiatives and corporate restructuring efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.